Loss of CDKN2A and p14^ARF expression occurs frequently in human nonmelanoma skin cancers

Keyphrases

• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 100%
• Non-melanoma Skin Cancer 100%
• P14ARF 100%
• P16INK4a 50%
• P53 Gene 50%
• Exon 1 50%
• Tumor 33%
• Genetic Abnormalities 33%
• TP53 mutation 33%
• CDKN2A Gene 33%
• P53 Pathway 33%
• Exon 2 33%
• Loss of Expression 33%
• Human Melanoma 16%
• Squamous Cell Carcinoma (SqCC) 16%
• Actinic Keratosis 16%
• Basal Cell Carcinoma 16%
• Immunostaining 16%
• Polymerase Chain Reaction 16%
• Retinoblastoma 16%
• Protein Expression 16%
• Tumor Suppressor 16%
• Cancer Cells 16%
• Human Chromosomes 16%
• Immunohistochemical Analysis 16%
• Genetic Modification 16%
• Tumor Progression 16%
• Genomic DNA (gDNA) 16%
• Gene Loss 16%
• P53 Tumor Suppressor Gene 16%
• Tumor Suppressor Activity 16%
• Tumor Protein p53 (TP53) 16%
• Strongly Positive 16%
• Active Role 16%
• Chromosome 9p21 16%
• Mutated Genes 16%
• Retinoblastoma Tumor Suppressor 16%
• Signature mutations 16%
• Ultraviolet-B (UV-B) 16%
• Homozygous Deletion 16%
• Retinoblastoma Pathway 16%

Biochemistry, Genetics and Molecular Biology

• P14arf 100%
• Cyclin Dependent Kinase Inhibitor 2A 100%
• P53 58%
• Exon 25%
• Protein P53 25%
• Retinoblastoma 25%
• Genetics 16%
• Tumor Suppressor Protein 16%
• Genomics 8%
• Cancer Cell 8%
• Gene Mutation 8%
• Protein Expression 8%
• Human Chromosome 8%
• Immunostaining 8%
• Polymerase Chain Reaction 8%
• Mutated Genes 8%
• Gene Loss 8%
• Tumor Progression 8%
• Tumor Suppressor Gene 8%